Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Objective

We aimed to investigate the effect of liraglutide treatment on heart function in type 2 diabetes (T2D) patients with subclinical heart failure.

Methods

Randomized open parallel-group trial. 62 T2D patients (45 male) with subclinical heart failure were randomized to either once daily liraglutide 1.8 mg, or glimepiride 4 mg, both add on to metformin 1 g twice a day. Mitral annular systolic (s′) and early diastolic (e′) velocities were measured at rest and during bicycle ergometer exercise, using tissue Doppler echocardiography. The primary endpoint was 18-week treatment changes in longitudinal functional reserve index (LFRI _{diastolic/systolic}).

Results

Clinical characteristics between groups (liraglutide = 33 vs. glimepiride = 29) were well matched. At baseline left ventricle ejection fraction (53.7 vs. 53.6%) and global longitudinal strain (−15.3 vs. −16.5%) did not differ between groups. There were no significant differences in mitral flow velocities between groups. For the primary endpoint, there was no treatment change [95% confidence interval] for: LFRI _diastolic (−0.18 vs. −0.53 [−0.28, 2.59; p = 0.19]), or LFRI _systolic (−0.10 vs. −0.18 [−1.0, 1.7; p = 0.54]); for the secondary endpoints, there was a significant treatment change in respect of body weight (−3.7 vs. −0.2 kg [−5.5, −1.4; p = 0.001]), waist circumference (−3.1 vs. −0.8 cm [−4.2, −0.4; p = 0.019]), and heart rate (HR) (6.3 vs. −2.3 bpm [−3.0, 14.2; p = 0.003]), with no such treatment change in hemoglobin A1c levels (−11.0 vs. −9.2 mmol/mol [−7.0, 2.6; p = 0.37]), between groups.

Conclusion

18-week treatment of liraglutide compared with glimepiride did not improve LFRI _{diastolic/systolic}, but however increased HR. There was a significant treatment change in body weight reduction in favor for liraglutide treatment.

Related collections

Most cited references 25

Record: found
Abstract: found
Article: not found

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Kenneth Margulies, Adrian Hernandez, Margaret M. Redfield … (2016)

Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.

0 comments Cited 225 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.

Lazaros A Nikolaidis, Sunil V. Mankad, George Sokos … (2004)

Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) 1.63+/-0.09, P 2.02+/-0.11, P<0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects. When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

0 comments Cited 219 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.

Anders Jorsal, Caroline Kistorp, Pernille Holmager … (2017)

To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

0 comments Cited 178 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Thomas Nyström: URI : http://frontiersin.org/people/u/96320

Yang Cao: URI : http://frontiersin.org/people/u/462547

Journal

Journal ID (nlm-ta): Front Endocrinol (Lausanne)

Journal ID (iso-abbrev): Front Endocrinol (Lausanne)

Journal ID (publisher-id): Front. Endocrinol.

Title: Frontiers in Endocrinology

Publisher: Frontiers Media S.A.

ISSN (Electronic): 1664-2392

Publication date (Electronic): 14 November 2017

Publication date Collection: 2017

Volume: 8

Electronic Location Identifier: 325

Affiliations

[1] ¹Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset , Stockholm, Sweden

[2] ²Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet , Stockholm, Sweden

[3] ³Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University , Örebro, Sweden

[4] ⁴Central Hospital , Karlstad, Sweden

[5] ⁵Institution of Medical Science, Örebro University , Örebro, Sweden

Author notes

Edited by: Jan Polák, Charles University, Czechia

Reviewed by: Jan Brož, Charles University, Czechia; Gergő A. Molnár, University of Pécs, Hungary; Amelia Filippelli, University of Salerno, Italy

*Correspondence: Thomas Nyström, thomas.nystrom@ 123456ki.se

Specialty section: This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology

Article

DOI: 10.3389/fendo.2017.00325

PMC ID: 5694660

PubMed ID: 29184539

SO-VID: e92ffa80-93ef-4e22-868f-8d91fdf35e00

License:

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

History

Date received : 13 July 2017

Date accepted : 02 November 2017

Page count

Figures: 2, Tables: 2, Equations: 0, References: 36, Pages: 8, Words: 6296

Funding

Funded by: Hjärt-Lungfonden 10.13039/501100003793

Funded by: Svenska Läkaresällskapet 10.13039/501100007687

Funded by: Stockholms Läns Landsting 10.13039/501100004348

Funded by: Novo Nordisk 10.13039/501100004191

Funded by: Svenska Sällskapet för Medicinsk Forskning 10.13039/501100003748

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 13

See all cited by

Most referenced authors 744

See all reference authors

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study

Read this article at

Abstract

Objective

Methods

Results

Conclusion

Related collections

Society for Endocrinology

Most cited references 25

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Page count

Funding

Categories

Comments

Comment on this article

Similar content 1,099

Cited by 13

Most referenced authors 744